Upper tract urothelial cancer is uncommon, but it requires careful assessment because it can arise anywhere along the lining of the kidney drainage system and ureter. Robotic nephroureterectomy for urothelial cancer is a specialist operation used when removal of the affected kidney, ureter and a small section of bladder is the safest and most appropriate treatment.
The decision to proceed is individual. It depends on the tumour’s grade and location, imaging findings, kidney function, previous bladder cancer, overall health and whether there is evidence that disease has spread. A urologist will discuss the expected benefit of surgery alongside the alternatives and the recovery required.
What is upper tract urothelial cancer?
Urothelial cells line the inside of the bladder, ureters and the collecting system of each kidney. Cancer arising from these cells in the kidney drainage system or ureter is called upper tract urothelial carcinoma.
Blood in the urine is a common presenting symptom, although it is not always visible. Some patients have flank discomfort, recurrent urinary tract symptoms or an abnormality found during imaging for another reason. Others have no symptoms. These signs can have causes other than cancer, but visible blood in the urine should always be assessed promptly.
Investigations commonly include a CT urogram, urine testing and cystoscopy to inspect the bladder. In selected cases, ureteroscopy allows the urologist to pass a fine telescope into the ureter or kidney drainage system to inspect the lesion and obtain a biopsy. Staging scans may also be needed before treatment is planned.
When is robotic nephroureterectomy recommended?
For high-risk, invasive or larger upper tract urothelial cancers, radical nephroureterectomy is generally the standard surgical treatment. This involves removal of the kidney, the full length of the ureter and a cuff of bladder where the ureter enters it. Leaving the lower end of the ureter behind can increase the risk of cancer recurring there, which is why complete removal is important.
Robotic nephroureterectomy may be recommended when a minimally invasive approach is suitable for the individual patient and the tumour can be safely treated this way. The robot does not perform surgery independently. It is a surgical platform controlled entirely by the surgeon, providing magnified three-dimensional vision and instruments designed for precise movement within the abdomen and pelvis.
Not every upper tract tumour requires removal of the whole kidney and ureter. Kidney-sparing treatment may be considered for selected low-risk tumours, small lesions or patients with reduced function in the opposite kidney. Options may include endoscopic laser treatment, segmental ureteric surgery or local treatment delivered into the upper urinary tract. These approaches preserve renal tissue but usually require closer surveillance and, in some circumstances, repeat procedures.
Conversely, open surgery may be preferable where there has been extensive previous abdominal surgery, complex anatomy, bulky disease or another factor that makes a robotic approach less appropriate. The surgical method is chosen for cancer control and patient safety, not for the technology alone.
How the robotic procedure is performed
A robotic nephroureterectomy is performed under general anaesthetic in hospital. Several small abdominal incisions are made to place the camera and robotic instruments. The kidney and ureter are carefully separated from surrounding structures, with blood vessels controlled and divided. The surgeon then removes the ureter down to its entry into the bladder, together with a small bladder cuff.
The specimen is removed through a small extension of one incision, usually in the lower abdomen. A urinary catheter is left in place while the bladder repair heals. Depending on the operation and the bladder closure, it may remain for several days to around two weeks. Some patients require a bladder X-ray study before the catheter is removed.
Lymph nodes may be removed if imaging, tumour features or the location of disease indicate this is appropriate. Lymph node dissection can provide staging information and may have a role in managing higher-risk disease, although the extent required varies between patients.
Potential benefits and limitations of a robotic approach
Compared with a traditional open incision, a robotic approach can offer smaller wounds, less postoperative pain, reduced blood loss and a shorter hospital stay for suitable patients. It can also assist with the precise pelvic dissection needed to remove the lower ureter and bladder cuff.
These benefits are not guaranteed. Recovery is influenced by age, general fitness, kidney function, the complexity of surgery and whether additional procedures are required. The most important outcome is complete and safe cancer surgery with appropriate pathological assessment. In some cases, a planned robotic procedure may need to be converted to an open operation if this is safer.
Risks to discuss before surgery
All major surgery carries risks. Your surgeon and anaesthetist will discuss your individual risk profile, including medicines such as blood thinners and any heart, lung or kidney conditions. Potential complications of nephroureterectomy include:
- bleeding that may require transfusion or a further procedure;
- infection, wound complications or a urine leak from the bladder repair;
- injury to nearby structures, including bowel or blood vessels;
- blood clots in the legs or lungs, chest complications and risks related to anaesthesia;
- reduced overall kidney function after removal of one kidney; and
- the possibility of cancer recurrence in the bladder, remaining urinary tract or elsewhere.
Most people can live well with one kidney, provided the remaining kidney is healthy. Before surgery, kidney function is measured and the opposite kidney is reviewed on imaging. This is particularly relevant for patients with diabetes, high blood pressure, previous kidney disease or impairment affecting both kidneys.
Hospital stay and recovery at home
Hospital stay after uncomplicated robotic surgery is often a few days, although it may be longer if recovery is slower or there are medical issues requiring observation. Early walking, breathing exercises, adequate pain relief and prevention of constipation are all part of postoperative care.
At home, fatigue is expected in the first few weeks. Gentle daily activity is encouraged, but heavy lifting, strenuous exercise and driving should wait until you are comfortable, mobile and no longer taking sedating pain medicine. The timing varies, though many patients need several weeks before resuming normal routines and longer for physically demanding work.
Contact the treating team promptly if you develop fever, worsening abdominal pain, persistent vomiting, increasing wound redness, calf swelling, chest pain, shortness of breath, heavy blood in the urine or problems with the catheter. Clear written discharge instructions should cover catheter care, medications, activity restrictions and who to call after hours.
Pathology, bladder treatment and surveillance
The final pathology report determines the tumour grade, depth of invasion, surgical margins and whether lymph nodes contain cancer. These results guide the next stage of care. Some patients with higher-risk features may be referred to a medical oncologist to discuss systemic treatment, either before or after surgery depending on the clinical situation and kidney function.
Urothelial cancer can recur in the bladder even after the affected kidney and ureter have been removed. For this reason, cystoscopy remains an important part of follow-up. In selected patients, a single dose of chemotherapy placed into the bladder soon after surgery may reduce the chance of a later bladder recurrence. This is only used when it is safe to do so and there is no concern about leakage from the bladder repair.
Follow-up usually includes regular cystoscopy, urine tests, kidney function blood tests and imaging. The schedule depends on the original tumour’s risk category and pathology. Ongoing surveillance is a central part of treatment, rather than an optional extra after surgery.
Planning specialist care
A consultation for suspected or confirmed upper tract urothelial cancer should bring together imaging, biopsy results where available, medication lists and relevant medical history. At Urology Health Adelaide, discussion of robotic surgery focuses on whether it is appropriate for the cancer and the patient, as well as the practical details of hospital treatment and recovery.
When facing a diagnosis of upper tract urothelial cancer, timely specialist assessment helps turn a complex decision into a clear treatment plan, with surgery and follow-up tailored to the findings that matter most.
Recent Comments